Lonza TheraPRO CHO Media System

Lonza has launched the TheraPRO CHO Media System, a cell culture platform designed to simplify processes and optimise productivity and protein quality when used with GS-CHO cell lines (a prevalent mammalian host cell for protein production). The product supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time to market.

Protein production can be challenging, and unexpected issues that arise during scale-up and production can increase costs and delay delivery of antibody therapies to patients. In order to address these challenges, Lonza developed a chemically defined, animal-component free, two-part production system that is easy to use and simplifies media preparation.

The product is fully scalable, from cell line development through bioprocess manufacturing, and is supported by technical experts with extensive experience in troubleshooting. It also delivers efficient performance, achieving high viable cell concentrations and more than 5 g/L protein titre during a 15-day culture cycle. This represents more than double the protein titre that can be produced using existing solutions on the market, the company says.

As the media system is designed to be versatile, it can be used with a variety of GS knockout CHO cell hosts, and it supports diverse clones with different metabolic profiles. All components are manufactured in ISO 13485 certified facilities in accordance with good manufacturing practices (GMP), for full product traceability and optimum lot-to-lot consistency. Users will receive a Drug Master File (DMF) and expert technical assistance with regulatory submissions to maximise their chances of success.